Actelion vs. Torrent: Consent Judgment in Macitentan Patent Dispute
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Actelion Pharmaceuticals Ltd. v. Torrent Pharmaceuticals Ltd. |
| Case Number | 1:24-cv-03990 (D.N.J.) |
| Court | U.S. District Court for the District of New Jersey |
| Duration | March 19, 2024 – April 18, 2024 30 days |
| Outcome | Plaintiff Win — Consent Judgment with Injunction & Validity Admission |
| Patents at Issue | |
| Accused Products | Torrent’s generic macitentan 10 mg oral tablets (ANDA No. 211107) |
Case Overview
The Parties
⚖️ Plaintiff
Swiss-headquartered biopharmaceutical company, a subsidiary of Johnson & Johnson, known for its leadership in pulmonary arterial hypertension (PAH) therapies.
🛡️ Defendant
Global generic pharmaceutical manufacturer based in India, whose U.S. subsidiary filed ANDA No. 211107 for generic macitentan.
Patents at Issue
This landmark case involved two key patents covering the blockbuster PAH drug OPSUMIT® (macitentan), which protect both the active pharmaceutical ingredient and its formulation or methods of use. These patents are registered with the U.S. Patent and Trademark Office (USPTO).
- • US7094781B2 — Covers pharmaceutical compositions and methods relating to macitentan.
- • US10946015B2 — Covers formulation or use claims related to the OPSUMIT® product.
Developing a generic drug product?
Ensure your product does not infringe existing pharmaceutical patents before regulatory submission.
The Verdict & Legal Analysis
Outcome
The case resolved via **Consent Judgment** in a remarkably swift 30-day period. Torrent Pharmaceuticals expressly **admitted the validity and enforceability** of U.S. Patent No. 7,094,781 and conceded that its proposed generic macitentan product would infringe prior to patent expiration. A **permanent injunction** was entered against Torrent, prohibiting any infringing activity related to ANDA No. 211107.
Key Legal Issues
This resolution reinforces the potency of the Hatch-Waxman Act, particularly **35 U.S.C. § 271(e)(2)**, which defines the filing of an ANDA for a patented drug as an act of infringement. Torrent’s explicit admission of validity and infringement stands out, as many ANDA litigations result in settlements without such a definitive concession. This binding judicial admission forecloses future challenges related to this ANDA, providing Actelion with robust and expedited protection for its macitentan patent estate in the District of New Jersey, a key venue for pharmaceutical IP disputes.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in pharmaceutical patent litigation. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all 2 related patents in this technology space
- See which companies are most active in PAH IP
- Understand claim scope and validity patterns
🔍 Check My Generic Product’s Risk
Run a comprehensive FTO analysis for your own active pharmaceutical ingredient (API) or formulation.
- Input your API description or technical features
- AI identifies potentially blocking formulation/method patents
- Get actionable regulatory pathway risk assessment
High Risk Area
Composition of matter patents for macitentan
2 Key Patents
Covering macitentan API & formulation
Complex Design-Around
Formulation and method of use claims
✅ Key Takeaways
Consent judgments with explicit validity admissions provide stronger protection than settlements silent on patent merit.
Search related case law →The District of New Jersey remains the preferred venue for Hatch-Waxman litigation due to judicial familiarity and favorable procedural environment.
Explore precedents →A 30-day resolution timeline is achievable in ANDA cases when leverage is clear and both parties are commercially motivated to resolve early.
Analyze litigation trends →Injunction scope should expressly cover affiliates, successors, and assigns to prevent corporate restructuring workarounds.
Review injunction examples →Frequently Asked Questions
The primary patent was U.S. Patent No. 7,094,781 (US7094781B2), designated the “Licensed Patent” in the consent judgment. U.S. Patent No. 10,946,015 (US10946015B2) was also identified among the patents involved in the litigation.
Torrent admitted that US7094781’s claims are valid, enforceable, and would be infringed by commercial activities related to ANDA No. 211107 covering generic macitentan 10 mg tablets. The parties resolved for undisclosed consideration, and a permanent injunction was entered.
It establishes a binding judicial record of US7094781’s validity in the context of ANDA No. 211107, and signals to other potential ANDA challengers that Actelion will enforce its patent estate aggressively and with speed.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- USPTO Patent Full-Text Database — US7094781B2
- PACER Case Lookup — 1:24-cv-03990
- FDA ANDA Database
- U.S. Patent and Trademark Office — Patent Search
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.